EP3787754A1 - Extract of shells of theobroma cacao beans for controlling rosacea and skin redness - Google Patents

Extract of shells of theobroma cacao beans for controlling rosacea and skin redness

Info

Publication number
EP3787754A1
EP3787754A1 EP19720687.3A EP19720687A EP3787754A1 EP 3787754 A1 EP3787754 A1 EP 3787754A1 EP 19720687 A EP19720687 A EP 19720687A EP 3787754 A1 EP3787754 A1 EP 3787754A1
Authority
EP
European Patent Office
Prior art keywords
extract
rosacea
theobroma cacao
theobroma
cosmetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19720687.3A
Other languages
German (de)
French (fr)
Inventor
Marie Françoise ARIES
Stéphane POIGNY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Dermo Cosmetique SA
Original Assignee
Pierre Fabre Dermo Cosmetique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Dermo Cosmetique SA filed Critical Pierre Fabre Dermo Cosmetique SA
Publication of EP3787754A1 publication Critical patent/EP3787754A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin

Definitions

  • the present invention relates to a shell extract of Theobroma cocoa beans and compositions containing this extract for application in the fields of cosmetics and dermatology to fight against skin redness.
  • the present invention relates to a shell extract of Theobroma cacao beans and compositions containing this extract for the control of rosacea.
  • the skin is the organ of the largest human body, nearly 2m 2 of surface. It plays several fundamental roles, including external protection, thermal regulation, hormonal synthesis and has an immune function.
  • the skin consists of three superimposed layers that are the epidermis, in permanent renewal, the dermis and the hypoderm which ensures the fibrous framework.
  • the skin's color, texture and quality also have an undeniable psychosocial function.
  • Sensitive skins have in common to react quickly and excessively to a change in temperature, cold, wind, irritating hygiene or toilet products, unsuitable care.
  • the redness of the face is the prerogative of the sensitive skins, these skins which are distinguished by an exacerbated reactivity of the skin and cutaneous vessels.
  • the redness is more or less intermittent, but always uncomfortable and embarrassing.
  • Intermittent redness also called “flush” is a reaction of acute vasodilation that may be due to a commonplace or a little “stressful” such as a question for a student, a job interview, a emotionally emotional or conflictual conversation but still a change in temperature that solicits the circulation of blood in the face.
  • a diet too hot, alcoholic beverages or certain foods can also cause this redness.
  • redness can occur in people with vaso- reactive skin, a cutaneous feature that can be familial; or skin aging: from 25 years the skin is more sensitive to redness.
  • redness can become permanent, especially in the cheeks. This is called erythrosis which is a diffuse but permanent redness localized most often on the cheeks in the form of red patches.
  • the rosacea represents an aggravation of the erythrose with appearance of small dilated vessels. When pimples appear and the redness becomes permanent, it is called rosacea. It was formerly known as "rosacea" because, in addition to redness, it also has pimples reminiscent of adolescent acne.
  • Rosacea is a chronic and progressive joint inflammatory dermatosis related to vascular relaxation. It is a condition that affects the small vessels of the face. It frequently affects fair-skinned people and can have significant psycho-emotional consequences.
  • the name of this pathology refers to the color characteristic that takes the face during the disease.
  • Rosacea is a fairly common disease, since in France 2 to 3% of the adult population is concerned. Women are particularly affected, since there are two women for a man suffering from rosacea.
  • ocular rosacea mainly affects the central part of the face and is characterized by facial redness or flushing, facial erythema, papules, pustules, telangiectasia and sometimes ocular lesions called ocular rosacea.
  • the soft tissue of the nose can swell and produce bulbous swelling called rhinophyma.
  • Rosacea evolves, but not obligatorily, over several years by exacerbations aggravated by different stimuli such as temperature variations, alcohol, spices, sun exposure or emotions.
  • the mechanisms of occurrence of rosacea are still very poorly understood.
  • vascular origin of the disease mainly affects the central part of the face and is characterized by facial redness or flushing, facial erythema, papules, pustules, telangiectasia and sometimes ocular lesions called ocular rosacea.
  • the soft tissue of the nose can swell and produce bulbous swelling called rhinophyma.
  • Rosacea evolves, but
  • Blood vessels are thought to carry an abnormality of functioning, especially in Nordic-type subjects with fair skin, light eyes and light hair. This geographical predisposition is found in France, where the disease is very rare in the south and much more common north of the Loire. On the other side of the Mediterranean, and especially on black skin, the disease is practically non-existent.
  • Erythematotelangiectatic rosacea It is mainly characterized by flushing and persistent central facial erythema. The presence of telangiectasia is common, but not essential to the diagnosis of this type. Central facial edema, burning and stinging, and roughness or desquamation are also sometimes observed.
  • Papulopustular rosacea it is characterized by persistent central facial erythema and transient papules and / or pustules distributed in the center of the face. However, papules and pustules can also affect periorifical areas, such as perioral, perineal or periocular. This type of rosacea is reminiscent of acne, but comedones are absent. But rosacea and acne can coexist. Patients with this type of rosacea sometimes complain of burning and stinging. This type is often observed before or at the same time as the previous type, including the presence of telangiectasia. These may be masked by persistent erythema and papules or pustules.
  • Rhinophyma it is manifested by a thickening of the skin, nodules with an irregular surface and swelling. Rhinophyma is the most common presentation, but phymatous rosacea can affect other areas, such as the chin, forehead, cheeks or ears. In patients with this type of rosacea, the presence of enlarged and prominent follicular openings is sometimes reported in the affected area, as well as telangiectasia. This type is often observed before or at the same time as types 1 or 2. In the case of rhinophyma, these additional stigmas may be particularly pronounced in the nasal region.
  • ocular or ophthalmic rosacea The diagnosis of ocular rosacea should be considered when a patient presents with one or more of the following eye signs and symptoms: tearful or bloodshot appearance, foreign body sensation, burning or stinging, dryness, itching , photosensitivity, blurred vision, telangiectasia of the conjunctiva and eyelid margin or erythema of the eyelid and periocular. Blepharitis, conjunctivitis and irregular margins of the eyelid are other signs that may be detected.
  • a chalazion or chronic staphylococcal infection manifested by a stye and the cause of which is a malfunction of the Meibomian glands is a common sign of ocular disease associated with rosacea.
  • the diagnosis of ocular rosacea is most often made when cutaneous signs and symptoms are also detected.
  • Corticosteroids can also be incriminated, especially in 2 situations.
  • the first is rosacea which is aggravated by the application of corticosteroids.
  • the second is the appearance of the disease following long-term use of this type of medicine, we even talk about steroid rosacea.
  • Oral treatments with tetracycline derivatives are problematic for several reasons but in particular for their non-negligible side effects.
  • Oral administration of tetracyclines, such as doxycycline may induce photosensitivity, or even phototoxicity or gastrointestinal disorders.
  • the application WO2002 / 074290 describes the topical use of at least one non-steroidal anti-inflammatory compound for treating rosacea, these compounds may be combined with a nitroimidazole compound. However, it is reported that the combination of this treatment induces significant side effects, including gastrointestinal and renal (Edwards, Br. J. Vener Dis., 56, 285-290, 1980).
  • the present invention thus relates to an extract of bean shells of Theobroma cacao for its use in the prevention and / or treatment of rosacea.
  • the present invention also relates to a cosmetic or dermatological composition
  • a cosmetic or dermatological composition comprising at least one shell extract of Theobroma cocoa beans and at least one excipient cosmetically or dermatologically acceptable for use in the prevention and / or treatment of rosacea.
  • this treatment or prevention is performed topically, which significantly reduces any systemic side effect.
  • the subject of the present invention is also an extract of bovine hulls of Theobroma cacao for its use in the prevention and / or treatment of cutaneous redness.
  • the subject of the present invention is also a cosmetic or dermatological composition
  • a cosmetic or dermatological composition comprising at least one extract of Theobroma cacao bean shells and at least one cosmetically or dermatologically acceptable excipient for its use in the prevention and / or treatment of cutaneous redness.
  • the subject of the present invention is also the cosmetic use of an extract of bean shells of Theobroma cacao to prevent and / or fight against skin rashes.
  • the subject of the present invention is also the cosmetic use of a cosmetic or dermatological composition
  • a cosmetic or dermatological composition comprising at least one extract of Theobroma cocoa bean shells and at least one cosmetically or dermatologically acceptable excipient for preventing and / or combating cutaneous redness.
  • Skin rash may be intermittent redness (i.e., flush) or erythrosis, with redness particularly localized to the cheeks.
  • bean shell extract of Theobroma cacao is intended to mean the bean shell extract product of one or more species of Theobroma cacao.
  • extractative product means the product obtained after extraction of Theobroma cacao bean shell with a solvent, referred to as extraction solvent, (ie a liquid solution in the extraction solvent ) optionally in a concentrated or dry form after partial or total evaporation of the extraction solvent.
  • hydrophilic extract is meant an extract obtained by the use of at least one hydrophilic solvent as extraction solvent. Preferably, it is an extract obtained by extraction with one or more hydrophilic solvents.
  • aqueous extract is meant an extract obtained by the use of at least one aqueous solvent as extraction solvent. Preferably, it is an extract obtained by extraction with one or more aqueous solvents.
  • hydro-glycolic extract an extract obtained by the use of at least one hydro-glycolic solvent as extraction solvent. Preferably, it is an extract obtained by extraction with one or more hydro-glycol solvents.
  • hydrophilic solvent is meant a solvent selected from the group consisting of water, C1 to C5 alcohols (for example ethanol), C3 to C5 glycols (for example butylene glycol), glycerol, polyol acetone, C1 to C5 alkyl esters (e.g., ethyl acetate, isopropyl acetate) and mixtures thereof.
  • C1 to C5 alcohols for example ethanol
  • C3 to C5 glycols for example butylene glycol
  • glycerol polyol acetone
  • C1 to C5 alkyl esters e.g., ethyl acetate, isopropyl acetate
  • aqueous solvent is meant a solvent selected from the group consisting of water alone and water in combination with one or more C1 to C5 alcohols (eg ethanol), one or more C3 to C5 glycols. and combinations thereof.
  • hydro-glycolic solvent is meant a mixture of water and at least one C3-C5 glycol, especially propylene glycol, butylene glycol, pentylene glycol or a combination thereof.
  • it is a water / butylene glycol mixture.
  • dry extract is meant in the sense of the present invention, an extract free of extraction solvent or support or containing only non-significant trace. Such a dry extract thus contains only material from the bean shells of Theobroma cacao. It may also contain insignificant traces of extraction solvent.
  • topical application is meant an application on the skin, mucous membranes and / or integuments, especially on the skin.
  • treatment or "treat” rosacea, it is intended to reduce and / or inhibit the development of rosacea and / or at least one of its symptoms.
  • prevention or “prevent” rosacea, it is intended to reduce and / or prevent the appearance of at least one of the symptoms of rosacea.
  • Rosacea symptom means persistent redness, burning and stinging, hot flashes or telangiectasia.
  • treatment or “treat” or “fight against” or “fight against” skin redness is meant to reduce and / or eliminate the development of redness of the skin.
  • prevention or “prevent” skin redness is meant to reduce and / or prevent the appearance of redness of the skin.
  • cosmetic or dermatologically acceptable is intended to mean that which is useful in the preparation of a cosmetic or dermatological composition, which is generally safe, non-toxic and neither biologically nor otherwise undesirable and which is acceptable for a particular cosmetic or dermatological composition.
  • cosmetic or dermatological use especially by topical application and / or oral administration.
  • cocoa or cocoa tree the cocoa tree (Theobroma cacao) is a small evergreen tree of the genus Theobroma family Sterculiaceae according to the classical classification, or Malvaceae according to the phylogenetic classification. It produces edible beans with different flavors depending on the varieties of cacao, from which cocoa, the basic product of chocolate, is made.
  • the cocoa tree is a tropical species native to Mexico. It grows naturally in the Orinoco Basin and the Amazon at low altitude, at the foot of the Andes Mountains. It is a tree that is 10 to 15 meters tall, cauliflora and evergreen. It flowers from three years and gives flowers, fruits and leaves all year round.
  • the pods contain many seeds, from 25 to 75, grouped in ears and called cocoa beans, rich in starch, fat and alkaloids. Each mature seed is surrounded by a pulp called mucilage.
  • the fresh beans collected in the pod are fermented and then dried to give the so-called cocoa beans which will be used for the preparation of the cocoa proper. These beans contain a purple embryo with 2 large fleshy cotyledons, curled around a remnant of albumen.
  • the beans are protected by a hard integument, the hull, which envelops them completely.
  • the cocoa beans are rich in xanthine bases and more particularly in theobromine and caffeine.
  • the hulls of cocoa beans have significant levels of polyphenols (anthocyanins, flavonoids).
  • the bean shell extract of Theobroma cacao is a liquid extract, more particularly a hydrophilic extract, more particularly an aqueous extract and even more particularly a hydro-glycolic extract.
  • This extract may in particular be obtained by extraction with at least one hydrophilic solvent, preferably with at least one aqueous solvent and even more preferably with at least one hydro-glycolic solvent.
  • this extract is obtained by extraction of the hulls of Theobroma cocoa beans, preferably previously crushed or crushed, for example previously crushed, using one or more hydro-glycolic solvent (s) ( s), such as a water / butylene glycol mixture, for example in a water / butylene glycol ratio of 25/75 to 40/60.
  • s hydro-glycolic solvent
  • the bean shell extract of Theobroma cacao according to the invention advantageously contains 45% to 65% by weight of caffeine relative to the weight of the dry extract.
  • the bean shell extract of Theobroma cacao according to the invention will also advantageously contain 1.5% to 3.0% by weight of theobromine relative to the weight of the dry extract.
  • the extract according to the present invention can be obtained by extraction of shells of Theobroma cocoa beans crushed with a water / butylene glycol mixture as extraction solvent, for example in a water / butylene glycol ratio. from 25/75 to 40/60.
  • the bean shell extract of Theobroma cacao obtainable by such an example of extraction will advantageously contain 1.5 to 2.1% by weight of caffeine and 0.05 to 0.09% by weight. in weight of theobromine relative to the total weight of the extract.
  • Such an extract advantageously contains 1 to 5%, especially 2 to 4% by weight of dry extract.
  • Such an extract may be used as it is (solution with the extraction solvent) or in the form of a concentrated extract or of a dry extract after partial or total evaporation of the extraction solvent.
  • the invention relates to an extract of bean shells of Theobroma cacao, in particular as defined above, for its use in the treatment and / or prevention of rosacea.
  • the invention also relates to the use of an extract of bovine hulls of Theobroma cacao, in particular as defined above, for the manufacture of a medicament for the prevention and / or treatment of rosacea.
  • the invention also relates to a method for preventing and / or treating rosacea comprising administering to an individual in need of an effective amount of coconut shell extract of Theobroma cacao, especially as defined herein. above.
  • the purpose of the invention is therefore to propose a treatment for rosacea, which in particular reduces the side effects for the patient.
  • this treatment is performed topically, which significantly reduces any systemic side effect.
  • Rosacea may be selected from the group consisting of erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea.
  • the subject of the present invention is also an extract of bean shells of Theobroma cacao, in particular as defined above, for its use in the prevention and / or the treatment of cutaneous redness.
  • the invention also relates to the use of an extract of bean shells of Theobroma cacao, in particular as defined above, for the manufacture of a medicament intended for the prevention and / or treatment of skin rashes.
  • the invention also relates to a method for the prevention and / or treatment of cutaneous redness comprising administering to an individual in need of an effective amount of a coconut shell extract of Theobroma cacao, in particular as defined above. above.
  • the present invention thus also aims at a cosmetic method for preventing and / or combating cutaneous redness comprising the use, preferably by topical application, of a shell extract of Theobroma cocoa beans, especially as defined above.
  • the use of Theobroma cocoa bean shell extract according to the invention is preferentially topically.
  • the skin rashes are as defined above.
  • the redness of the skin is localized in the cheeks.
  • the present invention also relates to a cosmetic or dermatological composition
  • a cosmetic or dermatological composition comprising at least one shell extract of Theobroma cocoa beans, in particular as defined above, with at least one cosmetically or dermatologically acceptable excipient, for its use in the treatment and / or prevention of rosacea.
  • the invention also relates to a method for preventing and / or treating rosacea comprising administering an individual in need of an effective amount of a cosmetic or dermatological composition comprising at least one shell extract of Theobroma cocoa beans, especially as defined above, with at least one cosmetically or dermatologically acceptable excipient.
  • the composition according to the invention is in a form suitable for topical application.
  • the present invention also relates to a cosmetic or dermatological composition comprising at least one shell extract of Theobroma cocoa beans, in particular as defined above, with at least one cosmetically or dermatologically acceptable excipient, for its use in the treatment and / or prevention of skin rashes.
  • the invention also relates to the use of a cosmetic or dermatological composition
  • a cosmetic or dermatological composition comprising at least one extract of bean shells of Theobroma cacao, in particular as defined above, with at least one cosmetically or dermatologically acceptable excipient, for the manufacture of a drug for the prevention and / or treatment of skin rashes.
  • the invention also relates to a method for preventing and / or treating cutaneous redness comprising administering to an individual in need of an effective amount of a cosmetic or dermatological composition comprising at least one extract of Theobroma bean shells. cocoa, especially as defined above, with at least one cosmetically or dermatologically acceptable excipient.
  • the subject of the present invention is also the cosmetic use of a cosmetic or dermatological composition comprising at least one extract of bean shells of Theobroma cacao, in particular as defined above, with at least one cosmetically or dermatologically acceptable excipient, for prevent and / or fight against skin rashes.
  • the present invention thus also aims at a cosmetic method for preventing and / or combating cutaneous redness comprising the use, preferably by topical application, of a cosmetic or dermatological composition comprising at least one extract of cocoa bean shells from Theobroma cacao, in particular as defined above, with at least one cosmetically or dermatologically acceptable excipient.
  • the skin rashes are as defined above.
  • the redness of the skin is localized in the cheeks.
  • the cosmetic or dermatological compositions according to the third or fourth aspect of the invention may be in the forms which are usually known for topical administration, that is to say in particular lotions, foams, gels, dispersions, emulsions , sprays, serums, masks or creams, jellies, especially micellar jellies, with excipients allowing in particular skin penetration to improve the properties and accessibility of the active ingredient.
  • it will be a cream, an emulsion, or a jelly.
  • compositions generally contain, besides the compounds of the extract according to the present invention, a physiologically acceptable medium, generally based on water or solvent, for example alcohols, ethers or glycols. They may also contain surfactants, complexing agents, preservatives, stabilizing agents, emulsifiers, thickeners, gelling agents, humectants, emollients, trace elements, essential oils, perfumes, dyes, mattifying agents, chemical or mineral filters, moisturizing agents, thermal waters, etc.
  • the compositions according to the present invention will comprise 0.1 to 5% by weight, preferably 0.5 to 4% by weight, more preferably 0.5 to 3% by weight, more preferably 1 to 2% by weight.
  • compositions according to the present invention will comprise 1% by weight of Theobroma cacao bean shell extract relative to the total weight of the composition. In a most preferred manner, the compositions according to the present invention will comprise 2% by weight of Theobroma cacao bean shell extract based on the total weight of the composition. In another equally preferred manner, the compositions according to the present invention will comprise 3% by weight of Theobroma cacao bean shell extract based on the total weight of the composition.
  • the extracts of Theobroma cacao bean shells used in the compositions according to the invention will advantageously comprise a solids content of 1% to 5%, preferably 2% to 4%, by weight relative to the total weight of the product. 'extract.
  • the compositions according to the present invention will comprise 0.001 to 0.25%, preferably 0.005 to 0.20%, more preferably 0.005 to 0.15%, even more preferably 0.01 to 0.10% of Theobroma cocoa bean shell extract by weight of dry extract relative to the total weight of the composition.
  • the extracts of Theobroma cacao bean shells used in the compositions according to the invention will advantageously comprise a solids content of 1% to 5%, preferably 2% to 4%, by weight relative to the total weight of the product. 'extract.
  • compositions may be made according to methods well known to those skilled in the art.
  • Rosacea is a chronic disorder characterized by inflammation and vascular abnormalities of the facial skin. Cutaneous biopsies in patients with rosacea are characterized by perivascular infiltrates associated with vasodilation. ⁇ 2 -adrenergic receptor agonists exhibit vasoconstrictor activity. New approaches are expected for the treatment of facial erythema of rosacea. A recent approach has been to reduce erythema by vasoconstricting cutaneous blood vessels by targeting both ⁇ -adrenergic receptors with oxymetazoline (selective oti-adrenergic receptors, Shanler and Ondon, Arch Dermatol, 143 (11), pp. 1369-1371, 2007) and brimonidine (selective ot2-adrenergic receptors, Fowler et al., J.
  • oxymetazoline selective oti-adrenergic receptors
  • ⁇ 2-adrenergic receptors belong to the broad family of 7-transmembrane G protein-coupled receptors. Agonists for ⁇ 2 -adrenergic receptors cause an increase in adenylate cyclase activity resulting in an increase in intracellular cAMP .
  • the purpose of this test is to evaluate the effects of a Theobroma cacao bean shell extract on the activity of human ⁇ 2-adrenergic receptors expressed in HEK-293 cells. This activity is measured by cAMP production.
  • a specific agonist of this subtype is added to the incubation medium, it is 3mM dexmedetomidine which will serve as a positive control.
  • the cAMP production that results is then quantified by the HTRF® (Homogeneous Time-Resolved) detection method. Fluorescence).
  • the results presented come from 3 independent experiments.
  • the extract tested in this study was obtained by the hydroglycolic extraction of Theobroma cacao bean shell using a water / butylene glycol mixture as an extraction solvent.
  • This extract comprises approximately 69.2% of butylene glycol, 27.5% of water and 3.3% of dry extract.
  • This is a commercial material Caobromine® UP, sold by the company Solabia.
  • the INCI name of this material Butylene glycol / Aqua / Theobroma cacao.
  • the CAS number of Theobroma cacao is: 84649-99-0.
  • Dexmedet Dexmedetominidine
  • Avg average
  • SEM standard error at the mean.
  • Dexmedetomidine at 3mM results in an ot2 B - adrenergic agonist response, inducing significant cAMP production. This result was expected and validates this experience.
  • the inventors thus demonstrate that an extract of bean shells of Theobroma cacao has a vasoconstrictor activity making it possible to reveal anti-redness properties.
  • VEGF Vascular Endothelial Growth Factor growth factor
  • VEGF Vascular Endothelial Growth Factor growth factor
  • VEGF increases vascular permeability, stimulates endothelial cell migration and proliferation, and induces neovascularization.
  • VEGF is secreted by several cell types, such as endothelial cells, lymphocytes and monocytes, but also keratinocytes. Its biological effects are mediated by VEGF-R1 and VEGF-R2 receptors. The cutaneous vascular network in adults is remarkably stable and does not activate angiogenesis.
  • angiogenesis is involved in the pathogenesis of several diseases including rosacea. This process of angiogenesis is associated with the inflammatory response where VEGF plays a crucial role, particularly in the recruitment of inflammatory cells from the blood to the inflamed tissue.
  • VEGF plays a crucial role, particularly in the recruitment of inflammatory cells from the blood to the inflamed tissue.
  • keratinocytes secrete VEGF and express VEGF-R whereas in the case of inflammatory skin diseases, VEGF and its receptor are overexpressed.
  • Rosacea is a chronic skin disease whose etiology remains poorly understood. Rosacea is characterized by vascular and inflammatory abnormalities of the skin of the face and the ocular surface. VEGF and its receptor are expressed in skin biopsies of patients with rosacea showing the likely importance of this growth factor in this pathology. Biopsies are characterized by perivascular infiltration associated with vasodilation. The endothelium expresses both VEGF receptors. Although VEGF is present in the epidermis and endothelium, VEGF is not expressed by the endothelium but rather by the infiltration of inflammatory immune cells such as lymphocytes and macrophages. The VEGF pathway may contribute to vascular changes and immune infiltration observed in rosacea.
  • the purpose of this study is to evaluate the possible effects of Theobroma cacao bean shell extract on the release of IL8 and VEGF (Steinhoff et al., JAAD, 69: S15).
  • Normal human keratinocytes were obtained from pieces of skin derived from surgical waste of mammary or abdominal plasty. The keratinocytes thus obtained are placed in culture on plates of 12 or 24 wells and are exposed for one hour to the compounds to be tested and then placed for 5 or 24h in a rosacea-like environment. Based on the article by Steinhoff et al., JAAD, 69: S15-26, 2013, the rosacea environment is mimicked by the mixture of: a mediator of inflammation selected from TNF activating agents, a mediator of innate immunity selected from TRP receptor activating agents (TRPV1, TRPA1) and a bacterial component which is LL37 peptide. The culture supernatant is then removed, centrifuged and frozen at -20 ° C. The productions of TNF activating agents, a mediator of innate immunity selected from TRP receptor activating agents (TRPV1, TRPA1) and a bacterial component which is LL37 peptide. The culture supernatant is then removed, centr
  • Ext shells of cocoa beans extract of bean shells of Theobroma cacao; Conc: concentration. ** p ⁇ 0.01 versus control.
  • Doxycycline is used as a reference inhibitor on the production of VEGF, the results are convincing, the use of doxycycline allowed to validate this test.
  • Theobroma cacao bean shell extract has a vascular component, anti-redness, decreasing the vasodilatation of the blood vessels of the face and reducing angiogenesis.
  • An extract according to the invention can be obtained by extraction of hulls of Theobroma cocoa beans crushed by a mixture of butylene glycol and water, followed by filtration.
  • Theobroma cocoa extract 3-4%

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to an extract of shells of Theobroma cacao beans or a cosmetic or dermatological composition containing such an extract, and to the applications thereof in the fields of cosmetics and dermatology for preventing and/or controlling skin redness. The invention particularly relates to an extract of shells of Theobroma cacao beans or a cosmetic or dermatological composition comprising said extract for preventing and/or treating rosacea.

Description

Extrait de coques de fèves de Theobroma cacao pour lutter contre la rosacée et les rougeurs cutanées  Theobroma cocoa bean shell extract for the fight against rosacea and redness of the skin
DOMAINE TECHNIQUE TECHNICAL AREA
La présente invention concerne un extrait de coques de fèves de Theobroma cacao et les compositions contenant cet extrait pour une application dans les domaines de la cosmétique et de la dermatologie pour lutter contre les rougeurs cutanées.  The present invention relates to a shell extract of Theobroma cocoa beans and compositions containing this extract for application in the fields of cosmetics and dermatology to fight against skin redness.
Plus particulièrement, la présente invention concerne un extrait de coques de fèves de Theobroma cacao et les compositions contenant cet extrait pour lutter contre la rosacée .  More particularly, the present invention relates to a shell extract of Theobroma cacao beans and compositions containing this extract for the control of rosacea.
ETAT DE LA TECHNIQUE ANTERIEURE STATE OF THE PRIOR ART
La peau est l'organe du corps humain le plus étendu, près de 2m2 de surface. Elle joue plusieurs rôles fondamentaux dont celui de protection vis-à-vis de l'extérieur, de régulation thermique, de synthèse hormonale et elle possède aussi une fonction immunitaire. La peau est constituée de trois couches superposées que sont l'épiderme, en renouvellement permanent, le derme et l'hypoderme qui assure la charpente fibreuse. La peau par sa couleur, sa texture et sa qualité possède en outre une incontestable fonction psychosociale. The skin is the organ of the largest human body, nearly 2m 2 of surface. It plays several fundamental roles, including external protection, thermal regulation, hormonal synthesis and has an immune function. The skin consists of three superimposed layers that are the epidermis, in permanent renewal, the dermis and the hypoderm which ensures the fibrous framework. The skin's color, texture and quality also have an undeniable psychosocial function.
Les peaux sensibles ont en commun de réagir rapidement et excessivement à un changement de température, au froid, au vent, à des produits d'hygiène ou de toilette irritants, à des soins inadaptés. Les rougeurs du visage sont l'apanage des peaux sensibles, ces peaux qui se singularisent par une réactivité exacerbée de la peau et des vaisseaux cutanés. Les rougeurs sont plus ou moins intermittentes, mais toujours désagréables et gênantes .  Sensitive skins have in common to react quickly and excessively to a change in temperature, cold, wind, irritating hygiene or toilet products, unsuitable care. The redness of the face is the prerogative of the sensitive skins, these skins which are distinguished by an exacerbated reactivity of the skin and cutaneous vessels. The redness is more or less intermittent, but always uncomfortable and embarrassing.
La rougeur intermittente, encore dénommée « flush » est une réaction de vasodilatation aiguë qui peut être due à une situation banale ou un peu « stressante » telle qu'une interrogation pour un étudiant, un entretien d' embauche, une conversation affectivement émouvante ou conflictuelle mais encore à un changement de température qui sollicite la circulation du sang au niveau du visage.Intermittent redness, also called "flush" is a reaction of acute vasodilation that may be due to a commonplace or a little "stressful" such as a question for a student, a job interview, a emotionally emotional or conflictual conversation but still a change in temperature that solicits the circulation of blood in the face.
Une alimentation trop chaude, des boissons alcoolisées ou certains aliments (épices, moutarde ...) peuvent aussi causer ces rougeurs . A diet too hot, alcoholic beverages or certain foods (spices, mustard ...) can also cause this redness.
Différents facteurs peuvent favoriser et aggraver ces rougeurs : les facteurs externes, comme le froid ou le soleil qui entraînent une accélération de la micro-circulation cutanée ; les facteurs internes comme les émotions, la consommation de café ou d'épices ; l'hérédité : les rougeurs peuvent apparaître chez des personnes ayant une peau vaso- réactive, une caractéristique cutanée qui peut être familiale ; ou encore le vieillissement cutané : dès 25 ans la peau est plus sensible aux rougeurs.  Various factors can promote and aggravate these redness: external factors, such as cold or the sun, which lead to an acceleration of cutaneous microcirculation; internal factors such as emotions, consumption of coffee or spices; heredity: redness can occur in people with vaso- reactive skin, a cutaneous feature that can be familial; or skin aging: from 25 years the skin is more sensitive to redness.
A la longue, les rougeurs peuvent devenir permanentes, notamment au niveau des joues. C'est ce qu'on appelle l'érythrose qui constitue une rougeur diffuse mais permanente localisée le plus souvent sur les joues sous forme de plaques rouges . In the long run, redness can become permanent, especially in the cheeks. This is called erythrosis which is a diffuse but permanent redness localized most often on the cheeks in the form of red patches.
La couperose représente une aggravation de l'érythrose avec apparition de petits vaisseaux dilatés. Lorsque des boutons apparaissent et que la rougeur devient permanente, on parle alors de rosacée. Elle était dénommée autrefois « l'acné rosacée », parce qu'en plus des rougeurs, elle comporte aussi des boutons qui rappellent l'acné des adolescents .  The rosacea represents an aggravation of the erythrose with appearance of small dilated vessels. When pimples appear and the redness becomes permanent, it is called rosacea. It was formerly known as "rosacea" because, in addition to redness, it also has pimples reminiscent of adolescent acne.
La rosacée est une dermatose inflammatoire commune chronique et progressive liée à une relaxation vasculaire. Il s'agit d'une affection qui touche les petits vaisseaux du visage. Elle touche fréquemment les personnes à peau claire et peut avoir des conséquences psycho-affectives importantes. Le nom de cette pathologie fait référence à la couleur caractéristique que prend le visage lors de la maladie. L'aspect général du visage faisant évoquer à tort un excès chronique de consommation d'alcool, la rosacée est une maladie socialement difficile à vivre, en particulier par les femmes. La rosacée est une maladie plutôt fréquente, puisqu' en France, 2 à 3% de la population adulte est concernée. Les femmes sont particulièrement touchées, puisque l'on compte deux femmes pour un homme souffrant de rosacée. Elle affecte principalement la partie centrale du visage et se caractérise par un rougissement du visage ou des bouffées de chaleur, un érythème facial, des papules, des pustules, une télangiectasie et parfois des lésions oculaires appelées rosacée oculaire. Dans des cas graves, particulièrement chez l'homme, le tissu mou du nez peut enfler et produire un gonflement bulbeux appelé rhinophyma. La rosacée évolue, mais de façon non obligatoire, sur plusieurs années par poussées aggravées par différents stimuli comme les variations de température, l'alcool, les épices, l'exposition solaire ou les émotions . Les mécanismes de survenue de la rosacée sont aujourd'hui encore très mal compris. Parmi les certitudes des scientifiques, il y a l'origine vasculaire de la maladie. Les vaisseaux sanguins seraient porteurs d'une anomalie de fonctionnement, en particulier chez des sujets de type nordique à peau claire, yeux clairs et cheveux clairs. Cette prédisposition géographique se retrouve en France, où la maladie est très rare dans le sud et beaucoup plus fréquente au nord de la Loire. De l'autre côté de la méditerranée, et particulièrement sur peau noire, la maladie est pratiquement inexistante. Rosacea is a chronic and progressive joint inflammatory dermatosis related to vascular relaxation. It is a condition that affects the small vessels of the face. It frequently affects fair-skinned people and can have significant psycho-emotional consequences. The name of this pathology refers to the color characteristic that takes the face during the disease. As the general appearance of the face is a chronic excess of alcohol abuse, rosacea is a socially difficult disease, especially for women. Rosacea is a fairly common disease, since in France 2 to 3% of the adult population is concerned. Women are particularly affected, since there are two women for a man suffering from rosacea. It mainly affects the central part of the face and is characterized by facial redness or flushing, facial erythema, papules, pustules, telangiectasia and sometimes ocular lesions called ocular rosacea. In severe cases, particularly in humans, the soft tissue of the nose can swell and produce bulbous swelling called rhinophyma. Rosacea evolves, but not obligatorily, over several years by exacerbations aggravated by different stimuli such as temperature variations, alcohol, spices, sun exposure or emotions. The mechanisms of occurrence of rosacea are still very poorly understood. Among the certainties of scientists, there is the vascular origin of the disease. Blood vessels are thought to carry an abnormality of functioning, especially in Nordic-type subjects with fair skin, light eyes and light hair. This geographical predisposition is found in France, where the disease is very rare in the south and much more common north of the Loire. On the other side of the Mediterranean, and especially on black skin, the disease is practically non-existent.
Il est commun de classifier la rosacée en 4 types en fonction de caractéristiques cliniques selon Wilkin et al., J. Am. Acad. Dermatol., 46(4) : 584-587, 2002.  It is common to classify rosacea into 4 types according to clinical characteristics according to Wilkin et al., J. Am. Acad. Dermatol., 46 (4): 584-587, 2002.
Les caractéristiques primaires comme les bouffées vasomotrices, l'érythème persistant, les papules et pustules, les télangiectasies et les caractéristiques secondaires comme les sensations de brûlure ou de piqûre, les plaques, les aspects secs de la peau, les œdèmes, les manifestations oculaires, les changements phymateux de la rosacée sont souvent observées en association. Tous ces signes permettent de répartir les patients dans ces quatre types, mais il est possible que des patients présentent simultanément des caractéristiques évocatrices de plus d'un type de rosacée. Primary features such as hot flushes, persistent erythema, papules and pustules, telangiectasia and secondary characteristics such as burning or stinging, plaques, dry skin, edema, ocular manifestations, phymatous changes of rosacea are often observed in association. All of these signs can be used to categorize patients into these four types, but it is possible for patients to simultaneously have characteristics suggestive of more than one type of rosacea.
La rosacée érythématotélangiectasique : elle se caractérise principalement par des bouffées vasomotrices et un érythème facial central persistant. La présence de télangiectasies est commune, mais non essentielle au diagnostic de ce type. Un œdème facial central, des sensations de brûlure et de piqûre et une rugosité ou desquamation sont également parfois observés.  Erythematotelangiectatic rosacea: It is mainly characterized by flushing and persistent central facial erythema. The presence of telangiectasia is common, but not essential to the diagnosis of this type. Central facial edema, burning and stinging, and roughness or desquamation are also sometimes observed.
La rosacée papulo-pustuleuse : elle se caractérise par un érythème facial central persistant et par des papules et/ou pustules transitoires distribuées au centre du visage. Toutefois, les papules et les pustules peuvent également toucher les régions péri-orificielles, comme les zones péribuccale, périnasale ou périoculaire . Ce type de rosacée rappelle l'acné, mais les comédons sont absents. Mais la rosacée et l'acné peuvent coexister. Les patients atteints de ce type de rosacée se plaignent parfois de sensations de brûlure et de piqûre. Ce type est souvent observé avant ou en même temps que le type précédent, y compris la présence de télangiectasies. Ces dernières risquent d'être masquées par l'érythème persistant et les papules ou pustules.  Papulopustular rosacea: it is characterized by persistent central facial erythema and transient papules and / or pustules distributed in the center of the face. However, papules and pustules can also affect periorifical areas, such as perioral, perineal or periocular. This type of rosacea is reminiscent of acne, but comedones are absent. But rosacea and acne can coexist. Patients with this type of rosacea sometimes complain of burning and stinging. This type is often observed before or at the same time as the previous type, including the presence of telangiectasia. These may be masked by persistent erythema and papules or pustules.
La rosacée phymateuse : elle se manifeste par un épaississement de la peau, des nodules à la surface irrégulière et une tuméfaction. Le rhinophyma est la présentation la plus commune, mais la rosacée phymateuse peut affecter d'autres zones, comme le menton, le front, les joues ou les oreilles. Chez les patients atteints de ce type de rosacée, la présence d'ouvertures folliculaires grossies et proéminentes est parfois rapportée dans la région affectée, ainsi que des télangiectasies . Ce type est souvent observé avant ou en même temps que les types 1 ou 2. En cas de rhinophyma, ces stigmates additionnels risquent d'être particulièrement prononcés dans la région nasale. - La rosacée oculaire ou ophtalmique : le diagnostic de rosacée oculaire doit être envisagé quand un patient présente un ou plusieurs des signes et symptômes oculaires suivants : aspect larmoyant ou injecté de sang, sensation de corps étranger, de brûlure ou de piqûre, sécheresse, démangeaisons, photosensibilité, vision floue, télangectiasie de la conjonctive et du bord de la paupière ou érythème de la paupière et périoculaire . Une blépharite, une conjonctivite et une irrégularité des bords de la paupière sont d'autres signes éventuellement détectés. Un chalazion ou une infection staphylococcique chronique se manifestant par un orgelet et dont la cause est un dysfonctionnement des glandes de Meibomius est un signe fréquent d'affection oculaire liée à une rosacée. Le diagnostic de rosacée oculaire est le plus souvent posé quand des signes et symptômes cutanés sont également détectés. Phosphate rosacea: it is manifested by a thickening of the skin, nodules with an irregular surface and swelling. Rhinophyma is the most common presentation, but phymatous rosacea can affect other areas, such as the chin, forehead, cheeks or ears. In patients with this type of rosacea, the presence of enlarged and prominent follicular openings is sometimes reported in the affected area, as well as telangiectasia. This type is often observed before or at the same time as types 1 or 2. In the case of rhinophyma, these additional stigmas may be particularly pronounced in the nasal region. - Ocular or ophthalmic rosacea: The diagnosis of ocular rosacea should be considered when a patient presents with one or more of the following eye signs and symptoms: tearful or bloodshot appearance, foreign body sensation, burning or stinging, dryness, itching , photosensitivity, blurred vision, telangiectasia of the conjunctiva and eyelid margin or erythema of the eyelid and periocular. Blepharitis, conjunctivitis and irregular margins of the eyelid are other signs that may be detected. A chalazion or chronic staphylococcal infection manifested by a stye and the cause of which is a malfunction of the Meibomian glands is a common sign of ocular disease associated with rosacea. The diagnosis of ocular rosacea is most often made when cutaneous signs and symptoms are also detected.
Enfin il existe d'autres formes plus rares de rosacées, en particulier la rosacée granulomateuse. Malgré sa fréquence, ses causes restent encore mal déterminées, et peut impliquer plusieurs facteurs. L'alimentation et les facteurs climatiques jouent un rôle dans la maladie et ont un impact sur ces symptômes. Il existe parfois chez des patients atteints de rosacée, un dysfonctionnement des veines du visage, qui se traduit par une stagnation du sang dans les vaisseaux de la face, entraînant en cascade la dilatation des vaisseaux, l'œdème et l'altération de l'endothélium.  Finally there are other rarer forms of rosaceae, especially granulomatous rosacea. Despite its frequency, its causes are still poorly defined, and may involve several factors. Diet and climatic factors play a role in the disease and have an impact on these symptoms. In patients with rosacea, there is sometimes a malfunction of the facial veins, which results in stagnation of the blood in the vessels of the face, resulting in cascade dilatation of the vessels, edema and alteration of the endothelium.
Les corticoïdes peuvent également être incriminés, notamment dans 2 situations. La première c'est la rosacée qui est aggravée par l'application de corticoïdes. La seconde c'est l'apparition de la maladie suite à l'utilisation au long cours de ce type de médicaments, on parle même de rosacée stéroïdienne . Corticosteroids can also be incriminated, especially in 2 situations. The first is rosacea which is aggravated by the application of corticosteroids. The second is the appearance of the disease following long-term use of this type of medicine, we even talk about steroid rosacea.
Les traitements par voie orale avec les dérivés de tétracycline sont problématiques pour plusieurs raisons mais en particulier pour leurs effets secondaires non négligeables. L'administration orale de tétracyclines , comme par exemple la doxycycline, peut induire une photosensibilité, voire même une phototoxicité ou encore des désordres gastro-intestinaux. Oral treatments with tetracycline derivatives are problematic for several reasons but in particular for their non-negligible side effects. Oral administration of tetracyclines, such as doxycycline, may induce photosensitivity, or even phototoxicity or gastrointestinal disorders.
La demande W02002/074290 décrit l'utilisation topique d'au moins un composé anti-inflammatoire non-stéroïdien pour traiter la rosacée, ces composés peuvent être associés à un composé nitro-imidazole . Cependant il est rapporté que la combinaison de ce traitement induit des effets secondaires significatifs, notamment gastro-intestinaux et rénaux (Edwards, Br. J. Vener Dis . , 56, 285-290, 1980) .  The application WO2002 / 074290 describes the topical use of at least one non-steroidal anti-inflammatory compound for treating rosacea, these compounds may be combined with a nitroimidazole compound. However, it is reported that the combination of this treatment induces significant side effects, including gastrointestinal and renal (Edwards, Br. J. Vener Dis., 56, 285-290, 1980).
Il existe donc un besoin de disposer de nouveaux actifs pour lutter contre les rougeurs cutanées et pour le traitement de la rosacée, qu'ils soient utilisables pendant de longues périodes avec des effets secondaires aussi limités que possible. There is therefore a need to have new assets to fight against redness of the skin and for the treatment of rosacea, they are usable for long periods with side effects as limited as possible.
RESUME DE L'INVENTION SUMMARY OF THE INVENTION
De façon surprenante, les inventeurs ont découvert qu'un extrait de coques de fèves de Theobroma cacao était doté d'une activité agoniste sur les récepteurs ot2B-adrénergiques (exemple 1) mais également de propriétés inhibitrices sur le facteur de croissance VEGF et anti-inflammatoires en inhibant la production d' IL8 (exemple 2) . Surprisingly, the inventors have discovered that an extract of bean shells of Theobroma cacao was endowed with an agonist activity on α 2 B -adrenergic receptors (example 1) but also with inhibitory properties on the VEGF and anti-growth factor. -Inflammatory by inhibiting the production of IL8 (Example 2).
La présente invention concerne ainsi un extrait de coques de fèves de Theobroma cacao pour son utilisation dans la prévention et/ou le traitement de la rosacée. The present invention thus relates to an extract of bean shells of Theobroma cacao for its use in the prevention and / or treatment of rosacea.
La présente invention concerne aussi une composition cosmétique ou dermatologique comprenant au moins un extrait de coques de fèves de Theobroma cacao et au moins un excipient cosmétiquement ou dermatologiquement acceptable pour son utilisation dans la prévention et/ou le traitement de la rosacée . The present invention also relates to a cosmetic or dermatological composition comprising at least one shell extract of Theobroma cocoa beans and at least one excipient cosmetically or dermatologically acceptable for use in the prevention and / or treatment of rosacea.
De préférence, ce traitement ou cette prévention est effectué (e) par voie topique, ce qui réduit considérablement tout effet secondaire systémique.  Preferably, this treatment or prevention is performed topically, which significantly reduces any systemic side effect.
La présente invention a également pour objet un extrait de coques de fèves de Theobroma cacao pour son utilisation dans la prévention et/ou le traitement des rougeurs cutanées. The subject of the present invention is also an extract of bovine hulls of Theobroma cacao for its use in the prevention and / or treatment of cutaneous redness.
La présente invention a également pour objet une composition cosmétique ou dermatologique comprenant au moins un extrait de coques de fèves de Theobroma cacao et au moins un excipient cosmétiquement ou dermatologiquement acceptable pour son utilisation dans la prévention et/ou le traitement des rougeurs cutanées.  The subject of the present invention is also a cosmetic or dermatological composition comprising at least one extract of Theobroma cacao bean shells and at least one cosmetically or dermatologically acceptable excipient for its use in the prevention and / or treatment of cutaneous redness.
La présente invention a également pour objet l'utilisation cosmétique d'un extrait de coques de fèves de Theobroma cacao pour prévenir et/ou lutter contre les rougeurs cutanées.  The subject of the present invention is also the cosmetic use of an extract of bean shells of Theobroma cacao to prevent and / or fight against skin rashes.
La présente invention a également pour objet l'utilisation cosmétique d'une composition cosmétique ou dermatologique comprenant au moins un extrait de coques de fèves de Theobroma cacao et au moins un excipient cosmétiquement ou dermatologiquement acceptable pour prévenir et/ou lutter contre les rougeurs cutanées.  The subject of the present invention is also the cosmetic use of a cosmetic or dermatological composition comprising at least one extract of Theobroma cocoa bean shells and at least one cosmetically or dermatologically acceptable excipient for preventing and / or combating cutaneous redness.
Les rougeurs cutanées peuvent être des rougeurs intermittentes (i.e. flushes) ou une érythrose, ces rougeurs étant particulièrement localisées au niveau des joues. DEFINITIONS  Skin rash may be intermittent redness (i.e., flush) or erythrosis, with redness particularly localized to the cheeks. DEFINITIONS
Par « extrait de coques de fèves de Theobroma cacao », on entend désigner le produit d'extraction de coques de fèves d'une ou plusieurs espèces de Theobroma cacao.  The term "bean shell extract of Theobroma cacao" is intended to mean the bean shell extract product of one or more species of Theobroma cacao.
Par « coques de fèves de Theobroma cacao », on entend désigner le tégument dur et fin qui enveloppe la fève de Theobroma cacao. Par « produit d'extraction », on entend le produit obtenu après extraction des de coques de fèves de Theobroma cacao avec un solvant, appelé solvant d'extraction, (c'est-à-dire une solution liquide dans le solvant d'extraction) éventuellement sous une forme concentrée ou sèche après évaporation partielle ou totale du solvant d'extraction. The term "bean shells of Theobroma cacao" refers to the hard, thin seed coat that surrounds the bean of Theobroma cacao. "Extractive product" means the product obtained after extraction of Theobroma cacao bean shell with a solvent, referred to as extraction solvent, (ie a liquid solution in the extraction solvent ) optionally in a concentrated or dry form after partial or total evaporation of the extraction solvent.
Par « extrait hydrophile », on entend un extrait obtenu par l'utilisation d'au moins un solvant hydrophile comme solvant d'extraction. De préférence, il s'agit d'un extrait obtenu par extraction à l'aide d'un ou plusieurs solvants hydrophiles.  By "hydrophilic extract" is meant an extract obtained by the use of at least one hydrophilic solvent as extraction solvent. Preferably, it is an extract obtained by extraction with one or more hydrophilic solvents.
Par « extrait aqueux », on entend un extrait obtenu par l'utilisation d'au moins un solvant aqueux comme solvant d'extraction. De préférence, il s'agit d'un extrait obtenu par extraction à l'aide d'un ou plusieurs solvants aqueux.  By "aqueous extract" is meant an extract obtained by the use of at least one aqueous solvent as extraction solvent. Preferably, it is an extract obtained by extraction with one or more aqueous solvents.
Par « extrait hydro-glycolique », on entend un extrait obtenu par l'utilisation d'au moins un solvant hydro-glycolique comme solvant d'extraction. De préférence, il s'agit d'un extrait obtenu par extraction à l'aide d'un ou plusieurs solvants hydro-glycoliques .  By "hydro-glycolic extract" is meant an extract obtained by the use of at least one hydro-glycolic solvent as extraction solvent. Preferably, it is an extract obtained by extraction with one or more hydro-glycol solvents.
Par « solvant hydrophile », on entend un solvant choisi dans le groupe constitué de l'eau, des alcools en Cl à C5 (par exemple éthanol) , des glycols en C3 à C5 (par exemple butylène glycol), du glycérol, de l'acétone, des esters d'alkyles en Cl à C5 (par exemple acétate d'éthyle, acétate d' isopropyle) et des mélanges de ceux-ci.  By "hydrophilic solvent" is meant a solvent selected from the group consisting of water, C1 to C5 alcohols (for example ethanol), C3 to C5 glycols (for example butylene glycol), glycerol, polyol acetone, C1 to C5 alkyl esters (e.g., ethyl acetate, isopropyl acetate) and mixtures thereof.
Par « solvant aqueux », on entend un solvant choisi dans le groupe constitué de l'eau seule et de l'eau en association avec un ou plusieurs alcools en Cl à C5 (par exemple éthanol), un ou plusieurs glycols en C3 à C5 et des combinaisons de ceux-ci.  By "aqueous solvent" is meant a solvent selected from the group consisting of water alone and water in combination with one or more C1 to C5 alcohols (eg ethanol), one or more C3 to C5 glycols. and combinations thereof.
Par « solvant hydro-glycolique », on entend un mélange d'eau et d'au moins un glycol en C3 à C5, notamment le propylène glycol, le butylène glycol, le pentylène glycol ou une combinaison de ceux-ci. Avantageusement, il s'agit d'un mélange eau / butylène glycol.  By "hydro-glycolic solvent" is meant a mixture of water and at least one C3-C5 glycol, especially propylene glycol, butylene glycol, pentylene glycol or a combination thereof. Advantageously, it is a water / butylene glycol mixture.
Par « extrait sec », on entend au sens de la présente invention, un extrait dépourvu de solvant d'extraction ou de support ou en contenant uniquement à l'état de trace non significative. Un tel extrait sec contient ainsi uniquement de la matière issue des coques de fèves de Theobroma cacao. Il peut contenir également des traces non significatives de solvant d'extraction. By "dry extract" is meant in the sense of the present invention, an extract free of extraction solvent or support or containing only non-significant trace. Such a dry extract thus contains only material from the bean shells of Theobroma cacao. It may also contain insignificant traces of extraction solvent.
Par « application topique », on entend une application sur la peau, les muqueuses et/ou les phanères, notamment sur la peau .  By "topical application" is meant an application on the skin, mucous membranes and / or integuments, especially on the skin.
Par le terme « traitement » ou « traiter » la rosacée, on entend diminuer et/ou inhiber le développement de la rosacée et/ou d'au moins un de ses symptômes.  By the term "treatment" or "treat" rosacea, it is intended to reduce and / or inhibit the development of rosacea and / or at least one of its symptoms.
Par le terme « prévention » ou « prévenir » la rosacée, on entend diminuer et/ou éviter l'apparition d'au moins un des symptômes de la rosacée.  By the term "prevention" or "prevent" rosacea, it is intended to reduce and / or prevent the appearance of at least one of the symptoms of rosacea.
Par « symptôme de la rosacée », on entend la rougeur persistante, des sensations de brûlure et de piqûre, des bouffées de chaleur ou la télangiectasie .  "Rosacea symptom" means persistent redness, burning and stinging, hot flashes or telangiectasia.
Par « rougeurs cutanées » on entend plus particulièrement les rougeurs cutanées intermittentes (telles que les flushes ou des rougeurs dues à des facteurs externes tels que le froid ou le vent) ou permanentes (telles que l ' érythrose ) , plus particulièrement localisées au niveau des joues.  "Skin rash" refers more particularly to intermittent cutaneous redness (such as flushes or redness due to external factors such as cold or wind) or permanent redness (such as erythrosis), more particularly localized at the level of the skin. play.
Par le terme « traitement » ou « traiter » ou « lutter contre » ou « lutte contre » les rougeurs cutanées, on entend diminuer et/ou supprimer le développement de la rougeur cutanée.  By the term "treatment" or "treat" or "fight against" or "fight against" skin redness is meant to reduce and / or eliminate the development of redness of the skin.
Par le terme « prévention » ou « prévenir » les rougeurs cutanées, on entend diminuer et/ou éviter l'apparition de la rougeur cutanée .  By the term "prevention" or "prevent" skin redness is meant to reduce and / or prevent the appearance of redness of the skin.
Dans la présente invention, on entend désigner par « cosmétiquement ou dermatologiquement acceptable » ce qui est utile dans la préparation d'une composition cosmétique ou dermatologique, qui est généralement sûre, non toxique et ni biologiquement ni autrement non souhaitable et qui est acceptable pour une utilisation cosmétique ou dermatologique, notamment par application topique et/ou par administration par voie orale. DESCRIPTION DETAILLEE In the present invention, the term "cosmetically or dermatologically acceptable" is intended to mean that which is useful in the preparation of a cosmetic or dermatological composition, which is generally safe, non-toxic and neither biologically nor otherwise undesirable and which is acceptable for a particular cosmetic or dermatological composition. cosmetic or dermatological use, especially by topical application and / or oral administration. DETAILED DESCRIPTION
Appelé aussi cacao ou cacaotier, le cacaoyer ( Theobroma cacao) est un petit arbre à feuilles persistantes du genre Theobroma de la famille des Sterculiacées selon la classification classique, ou des Malvacées selon la classification phylogénétique. Il produit des fèves comestibles aux saveurs différentes suivant les variétés de cacaoyer, à partir desquelles est fabriqué le cacao, le produit de base du chocolat. Le cacaoyer est une espèce tropicale originaire du Mexique. Il pousse naturellement dans le bassin de l'Orénoque et de l'Amazonie à basse altitude, au pied de la Cordillère des Andes. C'est un arbre qui mesure de 10 à 15 mètres de haut, cauliflore et à feuilles persistantes. Il fleurit à partir de trois ans et donne des fleurs, des fruits et des feuilles toute l'année. Il atteint son plein rendement 6 à 7 ans après plantation et vit jusqu'à 40 ans. Seulement une fleur sur environ 500 donne des fruits. L'arbre peut produire annuellement jusqu'à 100 000 fleurs. On trouve ainsi au même moment des fleurs et des fruits sur l'arbre. Ses fruits, les cabosses, sont de grosses baies allongées. Chaque cabosse peut peser jusqu'à 400g pour 15 à 20 cm de long. Elles ont la particularité de grossir à la fois sur les branches maîtresses amis aussi directement sur le tronc de l'arbre. Leurs caractéristiques sont très variables d'une population à l'autre mais aussi au sein d'une même population. La maturation des fruits dure, selon les génotypes, de 5 à 7 mois. En moyenne un arbre donne environ 150 cabosses par an, ce qui donne près de 6 kg de cacao. Les cabosses contiennent de nombreuses graines, de 25 à 75, regroupées en épis et appelées fèves de cacao, riches en amidon, en matières grasses et en alcaloïdes. Chaque graine mûre est entourée d'une pulpe appelée mucilage. Les fèves fraîches recueillies dans la cabosse sont mises à fermenter puis à sécher pour donner ce que l'on appelle les fèves de cacao qui serviront à la préparation du cacao proprement dit. Ces fèves renferment un embryon violet pourvu de 2 gros cotylédons charnus, recroquevillés autour d'un reste d'albumen. Les fèves sont protégées par un tégument dur, la coque, qui les enveloppe complètement. Les fèves de cacao sont riches en bases xanthiques et plus particulièrement en théobromine et en caféine. Par ailleurs, les coques de fèves de cacao présentent des teneurs non négligeables en polyphénols (anthocyanes , flavonoïdes) . Also called cocoa or cocoa tree, the cocoa tree (Theobroma cacao) is a small evergreen tree of the genus Theobroma family Sterculiaceae according to the classical classification, or Malvaceae according to the phylogenetic classification. It produces edible beans with different flavors depending on the varieties of cacao, from which cocoa, the basic product of chocolate, is made. The cocoa tree is a tropical species native to Mexico. It grows naturally in the Orinoco Basin and the Amazon at low altitude, at the foot of the Andes Mountains. It is a tree that is 10 to 15 meters tall, cauliflora and evergreen. It flowers from three years and gives flowers, fruits and leaves all year round. It reaches its full yield 6 to 7 years after planting and lives up to 40 years. Only one flower out of about 500 gives fruit. The tree can produce up to 100,000 flowers annually. At the same time, there are flowers and fruits on the tree. Its fruits, the pods, are large elongated berries. Each pod can weigh up to 400g for 15 to 20 cm long. They have the particularity of growing at the same time on the main branches friends also directly on the trunk of the tree. Their characteristics are very variable from one population to another but also within the same population. Depending on the genotype, fruit ripening lasts 5 to 7 months. On average one tree gives about 150 pods a year, which gives almost 6 kg of cocoa. The pods contain many seeds, from 25 to 75, grouped in ears and called cocoa beans, rich in starch, fat and alkaloids. Each mature seed is surrounded by a pulp called mucilage. The fresh beans collected in the pod are fermented and then dried to give the so-called cocoa beans which will be used for the preparation of the cocoa proper. These beans contain a purple embryo with 2 large fleshy cotyledons, curled around a remnant of albumen. The beans are protected by a hard integument, the hull, which envelops them completely. The cocoa beans are rich in xanthine bases and more particularly in theobromine and caffeine. In addition, the hulls of cocoa beans have significant levels of polyphenols (anthocyanins, flavonoids).
Selon un mode de réalisation de l'invention, l'extrait de coques de fèves de Theobroma cacao est un extrait liquide, plus particulièrement un extrait hydrophile, plus particulièrement encore un extrait aqueux et encore plus particulièrement un extrait hydro-glycolique . According to one embodiment of the invention, the bean shell extract of Theobroma cacao is a liquid extract, more particularly a hydrophilic extract, more particularly an aqueous extract and even more particularly a hydro-glycolic extract.
Cet extrait pourra notamment être obtenu par extraction avec au moins un solvant hydrophile, préférentiellement avec au moins un solvant aqueux et encore plus préférentiellement avec au moins un solvant hydro-glycolique.  This extract may in particular be obtained by extraction with at least one hydrophilic solvent, preferably with at least one aqueous solvent and even more preferably with at least one hydro-glycolic solvent.
Selon un mode de réalisation particulier, cet extrait est obtenu par extraction des coques de fèves de Theobroma cacao, de préférence préalablement concassées ou broyées, par exemple préalablement concassées, à l'aide d'un ou plusieurs solvant (s) hydro-glycolique ( s ) , tel qu'un mélange eau / butylène glycol, par exemple dans un rapport eau / butylène glycol de 25/75 à 40/60.  According to a particular embodiment, this extract is obtained by extraction of the hulls of Theobroma cocoa beans, preferably previously crushed or crushed, for example previously crushed, using one or more hydro-glycolic solvent (s) ( s), such as a water / butylene glycol mixture, for example in a water / butylene glycol ratio of 25/75 to 40/60.
L'extrait de coques de fèves de Theobroma cacao selon l'invention contient avantageusement 45% à 65% en poids de caféine par rapport au poids de l'extrait sec. L'extrait de coques de fèves de Theobroma cacao selon l'invention contiendra également avantageusement 1,5% à 3,0% en poids de théobromine par rapport au poids de l'extrait sec.  The bean shell extract of Theobroma cacao according to the invention advantageously contains 45% to 65% by weight of caffeine relative to the weight of the dry extract. The bean shell extract of Theobroma cacao according to the invention will also advantageously contain 1.5% to 3.0% by weight of theobromine relative to the weight of the dry extract.
Par exemple, l'extrait selon la présente invention peut être obtenu par extraction de coques de fèves de Theobroma cacao concassées à l'aide d'un mélange eau / butylène glycol comme solvant d'extraction, par exemple dans un rapport eau / butylène glycol de 25/75 à 40/60.  For example, the extract according to the present invention can be obtained by extraction of shells of Theobroma cocoa beans crushed with a water / butylene glycol mixture as extraction solvent, for example in a water / butylene glycol ratio. from 25/75 to 40/60.
L'extrait de coques de fèves de Theobroma cacao pouvant être obtenu par un tel exemple d' extraction contiendra avantageusement 1,5 à 2,1% en poids de caféine et 0,05 à 0,09% en poids de théobromine par rapport au poids total de l'extrait. Un tel extrait contient avantageusement 1 à 5%, notamment 2 à 4% en poids d'extrait sec. Un tel extrait pourra être utilisé en l'état (solution avec le solvant d'extraction) ou sous forme d'extrait concentré ou d'extrait sec après évaporation partielle ou totale du solvant d'extraction. The bean shell extract of Theobroma cacao obtainable by such an example of extraction will advantageously contain 1.5 to 2.1% by weight of caffeine and 0.05 to 0.09% by weight. in weight of theobromine relative to the total weight of the extract. Such an extract advantageously contains 1 to 5%, especially 2 to 4% by weight of dry extract. Such an extract may be used as it is (solution with the extraction solvent) or in the form of a concentrated extract or of a dry extract after partial or total evaporation of the extraction solvent.
Selon un premier aspect, l'invention concerne un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci- dessus, pour son utilisation dans le traitement et/ou la prévention de la rosacée. According to a first aspect, the invention relates to an extract of bean shells of Theobroma cacao, in particular as defined above, for its use in the treatment and / or prevention of rosacea.
L'invention concerne également l'utilisation d'un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, pour la fabrication d'un médicament destiné à la prévention et/ou au traitement de la rosacée.  The invention also relates to the use of an extract of bovine hulls of Theobroma cacao, in particular as defined above, for the manufacture of a medicament for the prevention and / or treatment of rosacea.
L'invention concerne également une méthode de prévention et/ou de traitement de la rosacée comprenant l'administration à un individu en ayant besoin d'une quantité efficace d'un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus.  The invention also relates to a method for preventing and / or treating rosacea comprising administering to an individual in need of an effective amount of coconut shell extract of Theobroma cacao, especially as defined herein. above.
Dans un mode de réalisation particulier, l'invention a ainsi pour but de proposer un traitement de la rosacée, qui diminue notamment les effets secondaires pour le patient. De préférence, ce traitement est effectué par voie topique, ce qui réduit considérablement tout effet secondaire systémique.  In a particular embodiment, the purpose of the invention is therefore to propose a treatment for rosacea, which in particular reduces the side effects for the patient. Preferably, this treatment is performed topically, which significantly reduces any systemic side effect.
La rosacée peut être choisie dans le groupe constitué de la rosacée érythématotelangiectasique, la rosacée papulo- pustuleuse, la rosacée phymateuse, et la rosacée oculaire. Selon un deuxième aspect, la présente invention a également pour objet un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, pour son utilisation dans la prévention et/ou le traitement des rougeurs cutanées.  Rosacea may be selected from the group consisting of erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea. According to a second aspect, the subject of the present invention is also an extract of bean shells of Theobroma cacao, in particular as defined above, for its use in the prevention and / or the treatment of cutaneous redness.
L'invention concerne également l'utilisation d'un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, pour la fabrication d'un médicament destiné à la prévention et/ou au traitement de rougeurs cutanées. The invention also relates to the use of an extract of bean shells of Theobroma cacao, in particular as defined above, for the manufacture of a medicament intended for the prevention and / or treatment of skin rashes.
L'invention concerne également une méthode de prévention et/ou de traitement de rougeurs cutanées comprenant l'administration à un individu en ayant besoin d'une quantité efficace d'un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus.  The invention also relates to a method for the prevention and / or treatment of cutaneous redness comprising administering to an individual in need of an effective amount of a coconut shell extract of Theobroma cacao, in particular as defined above. above.
La présente invention a également pour objet l'utilisation cosmétique d'un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, pour prévenir et/ou lutter contre les rougeurs cutanées.  The subject of the present invention is also the cosmetic use of an extract of bovine hulls of Theobroma cacao, in particular as defined above, for preventing and / or combating cutaneous redness.
La présente invention vise ainsi également une méthode cosmétique pour prévenir et/ou lutter contre les rougeurs cutanées comprenant l'utilisation, de préférence par application topique, d'un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus.  The present invention thus also aims at a cosmetic method for preventing and / or combating cutaneous redness comprising the use, preferably by topical application, of a shell extract of Theobroma cocoa beans, especially as defined above.
L'utilisation de l'extrait de coques de fèves de Theobroma cacao selon l'invention est préférentiellement par voie topique.  The use of Theobroma cocoa bean shell extract according to the invention is preferentially topically.
Les rougeurs cutanées sont telles que définies ci-dessus. De préférence, les rougeurs cutanées sont localisées au niveau des joues.  The skin rashes are as defined above. Preferably, the redness of the skin is localized in the cheeks.
Selon un troisième aspect, la présente invention concerne aussi une composition cosmétique ou dermatologique comprenant au moins un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, avec au moins un excipient cosmétiquement ou dermatologiquement acceptable, pour son utilisation dans le traitement et/ou la prévention de la rosacée .  According to a third aspect, the present invention also relates to a cosmetic or dermatological composition comprising at least one shell extract of Theobroma cocoa beans, in particular as defined above, with at least one cosmetically or dermatologically acceptable excipient, for its use in the treatment and / or prevention of rosacea.
L'invention concerne également l'utilisation d'une composition cosmétique ou dermatologique comprenant au moins un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, avec au moins un excipient cosmétiquement ou dermatologiquement acceptable, pour la fabrication d'un médicament destiné à la prévention et/ou au traitement de la rosacée .  The invention also relates to the use of a cosmetic or dermatological composition comprising at least one extract of bean shells of Theobroma cacao, in particular as defined above, with at least one cosmetically or dermatologically acceptable excipient, for the manufacture of a medicine for the prevention and / or treatment of rosacea.
L'invention concerne également une méthode de prévention et/ou de traitement de la rosacée comprenant l'administration à un individu en ayant besoin d'une quantité efficace d'une composition cosmétique ou dermatologique comprenant au moins un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, avec au moins un excipient cosmétiquement ou dermatologiquement acceptable. The invention also relates to a method for preventing and / or treating rosacea comprising administering an individual in need of an effective amount of a cosmetic or dermatological composition comprising at least one shell extract of Theobroma cocoa beans, especially as defined above, with at least one cosmetically or dermatologically acceptable excipient.
Selon un mode de réalisation particulier, la composition selon l'invention se présente sous une forme adaptée à une application topique. Selon un quatrième aspect, la présente invention concerne aussi une composition cosmétique ou dermatologique comprenant au moins un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, avec au moins un excipient cosmétiquement ou dermatologiquement acceptable, pour son utilisation dans le traitement et/ou la prévention des rougeurs cutanées .  According to a particular embodiment, the composition according to the invention is in a form suitable for topical application. According to a fourth aspect, the present invention also relates to a cosmetic or dermatological composition comprising at least one shell extract of Theobroma cocoa beans, in particular as defined above, with at least one cosmetically or dermatologically acceptable excipient, for its use in the treatment and / or prevention of skin rashes.
L'invention concerne également l'utilisation d'une composition cosmétique ou dermatologique comprenant au moins un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, avec au moins un excipient cosmétiquement ou dermatologiquement acceptable, pour la fabrication d'un médicament destiné à la prévention et/ou au traitement de rougeurs cutanées.  The invention also relates to the use of a cosmetic or dermatological composition comprising at least one extract of bean shells of Theobroma cacao, in particular as defined above, with at least one cosmetically or dermatologically acceptable excipient, for the manufacture of a drug for the prevention and / or treatment of skin rashes.
L'invention concerne également une méthode de prévention et/ou de traitement de rougeurs cutanées comprenant l'administration à un individu en ayant besoin d'une quantité efficace d'une composition cosmétique ou dermatologique comprenant au moins un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, avec au moins un excipient cosmétiquement ou dermatologiquement acceptable.  The invention also relates to a method for preventing and / or treating cutaneous redness comprising administering to an individual in need of an effective amount of a cosmetic or dermatological composition comprising at least one extract of Theobroma bean shells. cocoa, especially as defined above, with at least one cosmetically or dermatologically acceptable excipient.
La présente invention a également pour objet l'utilisation cosmétique d'une composition cosmétique ou dermatologique comprenant au moins un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, avec au moins un excipient cosmétiquement ou dermatologiquement acceptable, pour prévenir et/ou lutter contre les rougeurs cutanées. La présente invention vise ainsi également une méthode cosmétique pour prévenir et/ou lutter contre les rougeurs cutanées comprenant l'utilisation, de préférence par application topique, d'une composition cosmétique ou dermatologique comprenant au moins un extrait de coques de fèves de Theobroma cacao, notamment tel que défini ci-dessus, avec au moins un excipient cosmétiquement ou dermatologiquement acceptable. The subject of the present invention is also the cosmetic use of a cosmetic or dermatological composition comprising at least one extract of bean shells of Theobroma cacao, in particular as defined above, with at least one cosmetically or dermatologically acceptable excipient, for prevent and / or fight against skin rashes. The present invention thus also aims at a cosmetic method for preventing and / or combating cutaneous redness comprising the use, preferably by topical application, of a cosmetic or dermatological composition comprising at least one extract of cocoa bean shells from Theobroma cacao, in particular as defined above, with at least one cosmetically or dermatologically acceptable excipient.
L'utilisation de la composition cosmétique ou dermatologique selon l'invention est préférentiellement par voie topique.  The use of the cosmetic or dermatological composition according to the invention is preferably topically.
Les rougeurs cutanées sont telles que définies ci-dessus. De préférence, les rougeurs cutanées sont localisées au niveau des joues. Les compositions cosmétiques ou dermatologiques selon le troisième ou quatrième aspect de l'invention pourront se présenter sous les formes qui sont habituellement connues pour une administration topique, c'est à dire notamment les lotions, les mousses, les gels, les dispersions, les émulsions, les sprays, les sérums, les masques ou les crèmes, les gelées, notamment les gelées micellaires, avec des excipients permettant notamment une pénétration cutanée afin d'améliorer les propriétés et l'accessibilité du principe actif. Avantageusement, il s'agira d'une crème, d'une émulsion, ou d'une gelée.  The skin rashes are as defined above. Preferably, the redness of the skin is localized in the cheeks. The cosmetic or dermatological compositions according to the third or fourth aspect of the invention may be in the forms which are usually known for topical administration, that is to say in particular lotions, foams, gels, dispersions, emulsions , sprays, serums, masks or creams, jellies, especially micellar jellies, with excipients allowing in particular skin penetration to improve the properties and accessibility of the active ingredient. Advantageously, it will be a cream, an emulsion, or a jelly.
Ces compositions contiennent généralement, outre les composés de l'extrait selon la présente invention, un milieu physiologiquement acceptable, en général à base d'eau ou de solvant, par exemple des alcools, des éthers ou des glycols. Elles peuvent également contenir des agents tensioactifs, des agents complexant, des conservateurs, des agents stabilisants, des émulsifiants, des épaississants, des gélifiants, des humectants, des émollients, des oligo-éléments, des huiles essentielles, des parfums, des colorants, des agents matifiants, des filtres chimiques ou minéraux, des agents hydratants, des eaux thermales, etc. Avantageusement, les compositions selon la présente invention comprendront 0,1 à 5% en poids, de préférence 0,5 à 4% en poids, de manière encore préférée 0,5 à 3% en poids, de manière encore préférée 1 à 2% en poids d'extrait de coques de fèves de Theobroma cacao par rapport au poids total de la composition. D'une façon préférée, les compositions selon la présente invention comprendront 1% en poids d'extrait de coques de fèves de Theobroma cacao par rapport au poids total de la composition. D'une façon toute aussi préférée, les compositions selon la présente invention comprendront 2% en poids d'extrait de coques de fèves de Theobroma cacao par rapport au poids total de la composition. D'une autre façon toute aussi préférée, les compositions selon la présente invention comprendront 3% en poids d'extrait de coques de fèves de Theobroma cacao par rapport au poids total de la composition. Les extraits de coques de fèves de Theobroma cacao utilisés dans les compositions selon l'invention comprendront avantageusement une teneur d'extrait sec de 1% à 5%, de préférence de 2% à 4%, en poids par rapport au poids total de l'extrait. These compositions generally contain, besides the compounds of the extract according to the present invention, a physiologically acceptable medium, generally based on water or solvent, for example alcohols, ethers or glycols. They may also contain surfactants, complexing agents, preservatives, stabilizing agents, emulsifiers, thickeners, gelling agents, humectants, emollients, trace elements, essential oils, perfumes, dyes, mattifying agents, chemical or mineral filters, moisturizing agents, thermal waters, etc. Advantageously, the compositions according to the present invention will comprise 0.1 to 5% by weight, preferably 0.5 to 4% by weight, more preferably 0.5 to 3% by weight, more preferably 1 to 2% by weight. by weight of shell extract of Theobroma cocoa beans based on the total weight of the composition. In a preferred manner, the compositions according to the present invention will comprise 1% by weight of Theobroma cacao bean shell extract relative to the total weight of the composition. In a most preferred manner, the compositions according to the present invention will comprise 2% by weight of Theobroma cacao bean shell extract based on the total weight of the composition. In another equally preferred manner, the compositions according to the present invention will comprise 3% by weight of Theobroma cacao bean shell extract based on the total weight of the composition. The extracts of Theobroma cacao bean shells used in the compositions according to the invention will advantageously comprise a solids content of 1% to 5%, preferably 2% to 4%, by weight relative to the total weight of the product. 'extract.
Selon un autre mode de réalisation, les compositions selon la présente invention comprendront 0,001 à 0,25%, de préférence 0,005 à 0,20%, de manière encore préférée 0,005 à 0,15%, de manière encore plus préférée 0,01 à 0,10% d'extrait de coques de fèves de Theobroma cacao en poids d'extrait sec par rapport au poids total de la composition. Les extraits de coques de fèves de Theobroma cacao utilisés dans les compositions selon l'invention comprendront avantageusement une teneur d'extrait sec de 1% à 5%, de préférence de 2% à 4%, en poids par rapport au poids total de l'extrait.  According to another embodiment, the compositions according to the present invention will comprise 0.001 to 0.25%, preferably 0.005 to 0.20%, more preferably 0.005 to 0.15%, even more preferably 0.01 to 0.10% of Theobroma cocoa bean shell extract by weight of dry extract relative to the total weight of the composition. The extracts of Theobroma cacao bean shells used in the compositions according to the invention will advantageously comprise a solids content of 1% to 5%, preferably 2% to 4%, by weight relative to the total weight of the product. 'extract.
De telles compositions peuvent être fabriquées selon des procédés bien connus de l'homme du métier. Such compositions may be made according to methods well known to those skilled in the art.
Les exemples suivants illustrent l'invention sans en limiter la portée. Exemple 1 : test pharmacologique d'un extrait de coques de fèves de Theobroma cacao pour son activité ot2-adrénergique The following examples illustrate the invention without limiting its scope. EXAMPLE 1 Pharmacological Test of an Extract of Hull Shells of Theobroma Cocoa for its ot2-adrenergic Activity
La rosacée est un trouble chronique caractérisé par une inflammation et des anomalies vasculaires de la peau du visage. Des biopsies cutanées chez des patients atteints de rosacée sont caractérisées par des infiltrats périvasculaires associés à la vasodilatation. Les agonistes des récepteurs ot2-adrénergiques présentent une activité vasoconstrictrice . De nouvelles approches sont attendues pour le traitement de l'érythème facial de la rosacée. Une approche récente a été de réduire l'érythème par une vasoconstriction des vaisseaux sanguins cutanés en ciblant les deux récepteurs a-adrénergiques avec l ' oxymétazoline (sélectif des récepteurs oti-adrénergiques , Shanler et Ondon, Arch Dermatol, 143(11), pp 1369-1371, 2007) et la brimonidine (sélectif des récepteurs ot2-adrénergiques , Fowler et al., J. Rosacea is a chronic disorder characterized by inflammation and vascular abnormalities of the facial skin. Cutaneous biopsies in patients with rosacea are characterized by perivascular infiltrates associated with vasodilation. Α 2 -adrenergic receptor agonists exhibit vasoconstrictor activity. New approaches are expected for the treatment of facial erythema of rosacea. A recent approach has been to reduce erythema by vasoconstricting cutaneous blood vessels by targeting both α-adrenergic receptors with oxymetazoline (selective oti-adrenergic receptors, Shanler and Ondon, Arch Dermatol, 143 (11), pp. 1369-1371, 2007) and brimonidine (selective ot2-adrenergic receptors, Fowler et al., J.
Drugs dermatol. 12(6), pp 650-656, 2013) par leurs effets agonistes. Les récepteurs ot2-adrénergiques appartiennent à la grande famille des récepteurs à 7 domaines transmembranaires couplés aux protéines G. Les agonistes pour les récepteurs ot2- adrénergiques entraînent une augmentation de l'activité de l'adénylate cyclase résultant en une augmentation de l'AMPc intracellulaire. Drugs dermatol. 12 (6), pp 650-656, 2013) by their agonist effects. Α2-adrenergic receptors belong to the broad family of 7-transmembrane G protein-coupled receptors. Agonists for α 2 -adrenergic receptors cause an increase in adenylate cyclase activity resulting in an increase in intracellular cAMP .
Le but de ce test est d'évaluer les effets d'un extrait de coques de fèves de Theobroma cacao sur l'activité de récepteurs ot2-adrénergiques humains exprimés dans des cellules HEK-293. Cette activité est mesurée par la production d'AMPc. The purpose of this test is to evaluate the effects of a Theobroma cacao bean shell extract on the activity of human α2-adrenergic receptors expressed in HEK-293 cells. This activity is measured by cAMP production.
Protocole Protocol
L'étude a été réalisée sur des cellules HEK-293 transfectées avec le récepteur ot2-adrénergique humain. Un agoniste spécifique de ce sous-type est ajouté au milieu d'incubation, il s'agit de la dexmédétomidine à 3mM qui servira de contrôle positif. La production d'AMPc qui en découle est alors quantifiée par la méthode de détection HTRF® (Homogeneous Time-Resolved Fluorescence) . Les résultats présentés proviennent de 3 expériences indépendantes . The study was performed on HEK-293 cells transfected with the human α2-adrenergic receptor. A specific agonist of this subtype is added to the incubation medium, it is 3mM dexmedetomidine which will serve as a positive control. The cAMP production that results is then quantified by the HTRF® (Homogeneous Time-Resolved) detection method. Fluorescence). The results presented come from 3 independent experiments.
L'extrait testé dans cette étude a été obtenu par extraction hydroglycolique de coque de fèves de Theobroma cacao à l'aide d'une mélange eau / butylène glycol comme solvant d'extraction. Cet extrait comprend environ 69,2% de butylène glycol, 27,5% d'eau et 3,3% d'extrait sec. Il s'agit d'une matière commerciale Caobromine® UP, vendue par la société Solabia. Le nom INCI de cette matière : Butylène glycol / Aqua / Theobroma cacao. Le numéro CAS de Theobroma cacao est : 84649-99-0.  The extract tested in this study was obtained by the hydroglycolic extraction of Theobroma cacao bean shell using a water / butylene glycol mixture as an extraction solvent. This extract comprises approximately 69.2% of butylene glycol, 27.5% of water and 3.3% of dry extract. This is a commercial material Caobromine® UP, sold by the company Solabia. The INCI name of this material: Butylene glycol / Aqua / Theobroma cacao. The CAS number of Theobroma cacao is: 84649-99-0.
Résultats Results
Les concentrations d'AMPc produit par la stimulation du récepteur ot2-adrénergique par l'extrait selon l'invention et la dexmédétomidine sont représentées dans le tableau 1 ci-dessous.  The concentrations of cAMP produced by stimulation of the α 2 -adrenergic receptor by the extract according to the invention and dexmedetomidine are shown in Table 1 below.
Dexmedet : Dexmédétominidine ; Moy : moyenne ; SEM : erreur standard à la moyenne. Le traitement des cellules avec le composé de référence Dexmedet: Dexmedetominidine; Avg: average; SEM: standard error at the mean. Treatment of the cells with the reference compound
Dexmedetomidine à 3mM résulte en une réponse agoniste ot2B- adrénergique, en induisant une production d'AMPc importante. Ce résultat était attendu et permet de valider cette expérience.Dexmedetomidine at 3mM results in an ot2 B - adrenergic agonist response, inducing significant cAMP production. This result was expected and validates this experience.
Le traitement des cellules avec un extrait de coque de fèves de Theobroma cacao testé à 0,01, 0,1% et 3% p/v montre une réponse agoniste ot2-adrénergique qui apparait concentration-dépendante. L'effet agoniste ot2B-adrénergique de cet extrait à 0,3% (statistiquement significatif) est même comparable à celui du composé de référence testé à 3mM. Treatment of the cells with a shell extract of Theobroma cocoa beans tested at 0.01, 0.1% and 3% w / v shows an α2-adrenergic agonist response that appears concentration-dependent. The ot2 B -adrenergic agonist effect of this extract at 0.3% (statistically significant) is even comparable to that of the reference compound tested at 3mM.
Les inventeurs démontrent ainsi qu'un extrait de coques de fèves de Theobroma cacao possède une activité vasoconstrictrice permettant de révéler des propriétés anti-rougeur.  The inventors thus demonstrate that an extract of bean shells of Theobroma cacao has a vasoconstrictor activity making it possible to reveal anti-redness properties.
Exemple 2 : test pharmacologique d'un extrait de coques de fèves de Theobroma cacao pour son activité anti-VEGF et IL-8 EXAMPLE 2 Pharmacological Test of an Extract of Shell of Theobroma Cocoa Beans for its Anti-VEGF and IL-8 Activity
Le facteur de croissance VEGF (Vascular Endothélial Growth Factor) est une glycoprotéine dimérique, mitogène pour les cellules endothéliales. Il joue un rôle clé dans le processus physiologique ou pathologique de l'angiogenèse. Le VEGF augmente la perméabilité vasculaire, stimule la migration et la prolifération des cellules endothéliales et induit une néo- vascularisation. Le VEGF est sécrété par plusieurs types cellulaires, tels que les cellules endothéliales, les lymphocytes et monocytes mais aussi les kératinocytes. Ses effets biologiques sont médiés par les récepteurs VEGF-R1 et VEGF-R2. Le réseau vasculaire cutané chez l'adulte est remarquablement stable et n'active pas l'angiogenèse. Cependant, lors de processus pathologiques comme les maladies inflammatoires cutanées, la peau a le pouvoir d'initier un retour à l'homéostasie très rapide et efficace. Une régulation anormale de l'angiogenèse est impliquée dans la pathogenèse de plusieurs maladies dont la rosacée. Ce processus d'angiogenèse est associé avec la réponse inflammatoire où le VEGF joue un rôle crucial notamment dans le recrutement des cellules inflammatoires à partir du sang jusqu'au tissu inflammé. Chez l'homme, dans le cas d'une peau normale, les kératinocytes sécrètent du VEGF et expriment le VEGF-R alors que dans le cas de maladies inflammatoires de la peau, le VEGF et son récepteur sont surexprimés. VEGF (Vascular Endothelial Growth Factor) growth factor is a mitotic dimeric glycoprotein for endothelial cells. It plays a key role in the physiological or pathological process of angiogenesis. VEGF increases vascular permeability, stimulates endothelial cell migration and proliferation, and induces neovascularization. VEGF is secreted by several cell types, such as endothelial cells, lymphocytes and monocytes, but also keratinocytes. Its biological effects are mediated by VEGF-R1 and VEGF-R2 receptors. The cutaneous vascular network in adults is remarkably stable and does not activate angiogenesis. However, during pathological processes such as inflammatory skin diseases, the skin has the power to initiate a return to homeostasis very fast and effective. Abnormal regulation of angiogenesis is involved in the pathogenesis of several diseases including rosacea. This process of angiogenesis is associated with the inflammatory response where VEGF plays a crucial role, particularly in the recruitment of inflammatory cells from the blood to the inflamed tissue. In humans, in the case of normal skin, keratinocytes secrete VEGF and express VEGF-R whereas in the case of inflammatory skin diseases, VEGF and its receptor are overexpressed.
La rosacée est une maladie chronique de la peau dont l'étiologie reste peu comprise. La rosacée est caractérisée par des anormalités vasculaire et inflammatoire de la peau de la face et de la surface oculaire. Le VEGF et son récepteur sont exprimés dans des biopsies de peau de patients atteint de rosacée montrant l'importance probable de ce facteur de croissance dans cette pathologie. Les biopsies sont caractérisées par un infiltrat périvasculaire associé avec la vasodilatation. L'endothélium exprime les deux récepteurs du VEGF. Bien que le VEGF soit présent dans l'épiderme et l'endothélium, le VEGF n'est pas exprimé par l'endothélium mais plutôt par l'infiltration de cellules immunitaires inflammatoires telles que des lymphocytes et macrophages. La voie du VEGF pourrait contribuer aux changements vasculaires et l'infiltration immunitaire observée dans la rosacée. Rosacea is a chronic skin disease whose etiology remains poorly understood. Rosacea is characterized by vascular and inflammatory abnormalities of the skin of the face and the ocular surface. VEGF and its receptor are expressed in skin biopsies of patients with rosacea showing the likely importance of this growth factor in this pathology. Biopsies are characterized by perivascular infiltration associated with vasodilation. The endothelium expresses both VEGF receptors. Although VEGF is present in the epidermis and endothelium, VEGF is not expressed by the endothelium but rather by the infiltration of inflammatory immune cells such as lymphocytes and macrophages. The VEGF pathway may contribute to vascular changes and immune infiltration observed in rosacea.
Le but de cette étude est d'évaluer les effets possibles d'un extrait de coque de fèves de Theobroma cacao sur la libération d' IL8 et de VEGF (Steinhoff et al., JAAD, 69 : S15-The purpose of this study is to evaluate the possible effects of Theobroma cacao bean shell extract on the release of IL8 and VEGF (Steinhoff et al., JAAD, 69: S15).
26, 2013) . 26, 2013).
Protocole Protocol
Des kératinocytes normaux humains ont été obtenus à partir de morceaux de peau issus de déchets opératoires de plasties mammaires ou abdominales. Les kératinocytes ainsi obtenus sont placés en culture sur plaques de 12 ou 24 puits et sont exposés pendant une heure aux composés à tester, puis placés pendant 5 ou 24h dans un environnement de type rosacée. Sur la base de l'article de Steinhoff et al., JAAD, 69 : S15-26, 2013, l'environnement de rosacée est mimé par le mélange de : un médiateur de l'inflammation choisi parmi les agents activateurs de TNF, un médiateur de l'immunité innée choisi parmi les agents activateurs des récepteurs TRP (TRPV1, TRPA1 ) et un composant bactérien qui est le peptide LL37. Le surnageant de culture est alors enlevé, centrifugé et congelé à -20°C. Les productions de Normal human keratinocytes were obtained from pieces of skin derived from surgical waste of mammary or abdominal plasty. The keratinocytes thus obtained are placed in culture on plates of 12 or 24 wells and are exposed for one hour to the compounds to be tested and then placed for 5 or 24h in a rosacea-like environment. Based on the article by Steinhoff et al., JAAD, 69: S15-26, 2013, the rosacea environment is mimicked by the mixture of: a mediator of inflammation selected from TNF activating agents, a mediator of innate immunity selected from TRP receptor activating agents (TRPV1, TRPA1) and a bacterial component which is LL37 peptide. The culture supernatant is then removed, centrifuged and frozen at -20 ° C. The productions of
VEGF et d' IL-8 sont quantifiées par ELISA (Enzyme-Linked Immunosorbent Assay) . Un pourcentage d'inhibition de la production de VEGF et d'IL-8 après exposition aux différents composés testés est calculé. L'analyse statistique est réalisée en utilisant une analyse de variance à une voie (ANOVA) suivi du test de Dunnett. VEGF and IL-8 are quantified by ELISA (Enzyme-Linked Immunosorbent Assay). A percentage inhibition of the production of VEGF and IL-8 after exposure to the various compounds tested is calculated. The statistical analysis is performed using a one-way analysis of variance (ANOVA) followed by Dunnett's test.
Le même extrait que pour l'exemple 1 a été utilisé.  The same extract as for Example 1 was used.
Résultats Results
Les résultats sont résumés dans le tableau 2 ci-dessous : The results are summarized in Table 2 below:
Ext coques de fèves de Th cacao : extrait de coques de fèves de Theobroma cacao ; Conc : concentration. **p<0.01 versus contrôle .  Ext shells of cocoa beans: extract of bean shells of Theobroma cacao; Conc: concentration. ** p <0.01 versus control.
La doxycycline est utilisée comme inhibiteur de référence sur la production du VEGF, les résultats sont probants, l'utilisation de la doxycycline a permis de valider ce test. Doxycycline is used as a reference inhibitor on the production of VEGF, the results are convincing, the use of doxycycline allowed to validate this test.
L'extrait de coque de fèves de Theobroma cacao testé à deux concentrations inhibe fortement et statistiquement la production de VEGF après 5h et 24 H de stimulation. De même la production de la cytokine inflammatoire IL-8 est réduite de façon statistique et concentration-dépendante par l'extrait de coque de fèves de Theobroma cacao.  The shell extract of Theobroma cocoa beans tested at two concentrations strongly and statistically inhibits the production of VEGF after 5h and 24h of stimulation. Similarly, the production of the inflammatory cytokine IL-8 is statistically and concentration-dependent reduced by Theobroma cacao bean shell extract.
Ainsi, par l'activité anti-VEGF, l'extrait de coques de fèves de Theobroma cacao présente une composante vasculaire, anti rougeur, diminuant la vasodilatation des vaisseaux sanguins de la face et réduisant l'angiogenèse. Thus, by the anti-VEGF activity, Theobroma cacao bean shell extract has a vascular component, anti-redness, decreasing the vasodilatation of the blood vessels of the face and reducing angiogenesis.
De même, l'extrait de coques de fèves de Theobroma cacao induit une inhibition de l'expression protéique d' IL8 in vitro sur des cellules stimulées par un environnement de type rosacée, démontrant une activité anti-inflammatoire.  Similarly, Theobroma cocoa bean shell extract induces an inhibition of IL8 protein expression in vitro on cells stimulated by a rosacea-like environment, demonstrating anti-inflammatory activity.
Exemples 3 : Préparation d'un extrait selon l'invention Un extrait selon l'invention peut être obtenu par extraction de coques de fèves de Theobroma cacao concassées par un mélange de butylène glycol et d'eau, puis filtration. Composition obtenue : Examples 3 Preparation of an Extract According to the Invention An extract according to the invention can be obtained by extraction of hulls of Theobroma cocoa beans crushed by a mixture of butylene glycol and water, followed by filtration. Composition obtained:
Butylène glycol : 60-70%  Butylene glycol: 60-70%
Eau : 25-35%  Water: 25-35%
Extrait Theobroma cacao : 3-4%  Theobroma cocoa extract: 3-4%

Claims

REVENDICATIONS
1. Extrait de coques de fèves de Theobroma cacao pour son utilisation dans le traitement et/ou la prévention de la rosacee . 1. Theobroma cocoa bean shell extract for its use in the treatment and / or prevention of rosaceae.
2. Extrait de coques de fèves de Theobroma cacao pour son utilisation selon la revendication 1, caractérisé en ce que la rosacée est choisie dans le groupe constitué de la rosacée érythématotelangiectasique, la rosacée papulo- pustuleuse, la rosacée phymateuse, et la rosacée oculaire. 2. The cocobia bean shell extract for its use according to claim 1, characterized in that the rosacea is selected from the group consisting of erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea.
3. Extrait de coques de fèves de Theobroma cacao pour son utilisation dans le traitement et/ou la prévention de rougeurs cutanées. 3. Theobroma cocoa bean shell extract for its use in the treatment and / or prevention of skin rashes.
4. Extrait de coques de fèves de Theobroma cacao pour son utilisation selon l'une quelconque des revendications 1 à 3, caractérisé en ce que ledit extrait est destiné à être appliqué par voie topique. 4. Extract of bean shells Theobroma cacao for use according to any one of claims 1 to 3, characterized in that said extract is intended to be applied topically.
5. Extrait de coques de fèves de Theobroma cacao pour son utilisation selon l'une quelconque des revendications 1 à5. Theobroma cacao bean shell extract for its use according to any one of claims 1 to
4, caractérisé en ce que l'extrait est un extrait aqueux. 4, characterized in that the extract is an aqueous extract.
6. Extrait de coques de fèves de Theobroma cacao pour son utilisation selon l'une quelconque des revendications 1 à6. Theobroma cacao bean shell extract for use as claimed in any one of claims 1 to
5, caractérisé en ce que l'extrait est un extrait hydroglycolique . 5, characterized in that the extract is a hydroglycolic extract.
7. Utilisation cosmétique, de préférence topique, d'un extrait de coques de fèves de Theobroma cacao pour prévenir et/ou lutter contre les rougeurs cutanées. 7. Cosmetic use, preferably topical, of an extract of cockles of Theobroma cacao beans to prevent and / or fight against redness of the skin.
8. Utilisation cosmétique selon la revendication 7, caractérisée en ce que l'extrait de coques de fèves de Theobroma cacao est un extrait aqueux, tel qu'un extrait hydroglycolique . 8. Cosmetic use according to claim 7, characterized in that the shell extract of Theobroma cocoa beans is an aqueous extract, such as a hydroglycolic extract.
9. Composition dermatologique ou cosmétique comprenant au moins un extrait de coques de fèves de Theobroma cacao avec au moins un excipient dermatologiquement ou cosmétiquement acceptable pour son utilisation dans le traitement et/ou la prévention de la rosacée. 9. Dermatological or cosmetic composition comprising at least one shell extract of Theobroma cacao beans with at least one dermatologically or cosmetically acceptable excipient for use in the treatment and / or prevention of rosacea.
10. Composition dermatologique ou cosmétique pour son utilisation selon la revendication 9, caractérisée en ce que la rosacée est choisie dans le groupe constitué de la rosacée érythématotelangiectasique, la rosacée papulo- pustuleuse, la rosacée phymateuse, et la rosacée oculaire. 10. Dermatological or cosmetic composition for its use according to claim 9, characterized in that the rosacea is selected from the group consisting of erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea.
11. Composition dermatologique ou cosmétique pour son utilisation dans le traitement et/ou la prévention de rougeurs cutanées. 11. Dermatological or cosmetic composition for its use in the treatment and / or prevention of skin rashes.
12. Composition dermatologique ou cosmétique pour son utilisation selon l'une quelconque des revendications 9 à 11, caractérisée en ce qu'elle comprend 0,1 à 5% en poids, de préférence 0,5 à 4% en poids d'extrait de coques de fèves de Theobroma cacao par rapport au poids total de la composition . 12. Dermatological or cosmetic composition for use according to any one of claims 9 to 11, characterized in that it comprises 0.1 to 5% by weight, preferably 0.5 to 4% by weight of hulls of Theobroma cacao beans in relation to the total weight of the composition.
13. Composition dermatologique ou cosmétique pour son utilisation selon l'une quelconque des revendications 9 à13. Dermatological or cosmetic composition for its use according to any one of claims 9 to
12, caractérisée en ce qu'elle est destinée à une application topique. 12, characterized in that it is intended for topical application.
14. Composition dermatologique ou cosmétique pour son utilisation selon l'une quelconque des revendications 9 à 13, caractérisée en ce que l'extrait de coques de fèves de Theobroma cacao est un extrait aqueux, tel qu'un extrait hydroglycolique . 14. Dermatological or cosmetic composition for its use according to any one of claims 9 to 13, characterized in that the shell extract of beans Theobroma cacao is an aqueous extract, such as a hydroglycolic extract.
15. Utilisation cosmétique, de préférence topique, d' une composition dermatologique ou cosmétique comprenant au moins un extrait de coques de fèves de Theobroma cacao avec au moins un excipient dermatologiquement ou cosmétiquement acceptable pour prévenir et/ou lutter contre les rougeurs cutanées . 15. Cosmetic use, preferably topical, of a dermatological or cosmetic composition comprising at least one extract of bovine hulls of Theobroma cacao with at least one dermatologically or cosmetically acceptable excipient for preventing and / or combating cutaneous redness.
16. Utilisation cosmétique selon la revendication 15, caractérisée en ce que l'extrait de coques de fèves de16. Cosmetic use according to claim 15, characterized in that the bean shell extract
Theobroma cacao est un extrait aqueux, tel qu'un extrait hydroglycolique . Theobroma cacao is an aqueous extract, such as a hydroglycolic extract.
EP19720687.3A 2018-05-04 2019-05-03 Extract of shells of theobroma cacao beans for controlling rosacea and skin redness Withdrawn EP3787754A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1853865A FR3080767B1 (en) 2018-05-04 2018-05-04 THEOBROMA CACAO BEAN EXTRACT TO FIGHT AGAINST ROSACEA AND SKIN REDNESS
PCT/EP2019/061448 WO2019211470A1 (en) 2018-05-04 2019-05-03 Extract of shells of theobroma cacao beans for controlling rosacea and skin redness

Publications (1)

Publication Number Publication Date
EP3787754A1 true EP3787754A1 (en) 2021-03-10

Family

ID=63722473

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19720687.3A Withdrawn EP3787754A1 (en) 2018-05-04 2019-05-03 Extract of shells of theobroma cacao beans for controlling rosacea and skin redness

Country Status (7)

Country Link
EP (1) EP3787754A1 (en)
KR (1) KR20210005203A (en)
BR (1) BR112020021956A2 (en)
CA (1) CA3098361A1 (en)
FR (1) FR3080767B1 (en)
MX (1) MX2020011473A (en)
WO (1) WO2019211470A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142037A0 (en) 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
FR2838055B1 (en) * 2002-04-05 2006-06-09 Cep NOVEL USE OF A COCOA EXTRACT AND COSMETIC AND / OR DERMATOLOGICAL COMPOSITIONS THEREFOR
FR2855050B1 (en) * 2003-05-22 2008-07-04 Oreal PROCESS FOR THE COSMETIC TREATMENT OF REDNESS
FR2857588B1 (en) * 2003-07-17 2007-11-30 Oreal USE OF BETA-ENDORPHINE, AGENTS EXERCISING BETA-ENDORPHINE-LIKE ACTIVITY IN COSMETICS AND DERMATOLOGY

Also Published As

Publication number Publication date
FR3080767A1 (en) 2019-11-08
WO2019211470A1 (en) 2019-11-07
FR3080767B1 (en) 2020-10-30
KR20210005203A (en) 2021-01-13
MX2020011473A (en) 2020-12-07
BR112020021956A2 (en) 2021-01-26
CA3098361A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
EP3393488B1 (en) Composition comprising an ambora extract and a green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant pruritus and senile pruritus
FR2946879A1 (en) EXTRACT OF WHOLE SEEDS OF MORINGA SP. AND ITS USE IN COSMETIC AND / OR DERMATOLOGICAL COMPOSITIONS.
FR2938439A1 (en) EXTRACT OF AERIAL PARTS OF OATS HARVESTED BEFORE EPIAISON
EP2364135B1 (en) Drug or dermatological composition containing an avocado peptide extract for treating and preventing intern pruritus
EP3203981B1 (en) Deglycation activity of a combination of an extract of salvia miltiorrhiza and niacin and/or niacinamide
FR3069779A1 (en) USE OF A NEPHELIUM LAPPACEUM PERICARP EXTRACT FOR MOISTURIZING SKIN AND / OR MUCOUS MEMBRANES
FR3061434B1 (en) COSMETIC COMPOSITION COMPRISING AN ASSOCIATION OF PONGAMIA OIL AND PENTYLENE GLYCOL 4-T-BUTYLCYCLOHEXANOL FOR CONTROLLING ROSACEA
WO2012172199A1 (en) Composition based on camellia japonica and polygonum hydropiper for protecting the skin
EP0831865B1 (en) Hair composition comprising a myrtle extract, preparation process and utilization particularly for an anti-dandruff treatment
FR2885050A1 (en) Slimming cosmetic and/or pharmaceutical composition, useful for treatment of adipocytes of skin, comprises cocoa extract containing polyphenols
FR3013985A1 (en) MOISTURIZING COMPOSITIONS COMPRISING AT LEAST ONE CAESALPINIA SPINOSA EXTRACT WITH AT LEAST VASELIN AND GLYCERIN
EP3890698A1 (en) Garcinia mangostana extract for promoting hair growth
EP3787754A1 (en) Extract of shells of theobroma cacao beans for controlling rosacea and skin redness
EP3829626A1 (en) Lespedeza capitata extract for use in the field of hair care
EP2811978B1 (en) Use of an apple tree bark extract in a cosmetic anti-ageing composition
EP2811977B1 (en) Use of an apple tree leaf extract in a cosmetic skin-firming composition
FR3047667B1 (en) NOVEL COSMETIC OR DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF REDNESS
FR3052979A1 (en) BIOMIMETIC COSMETIC COMPOSITION COMPRISING AN ASSOCIATION OF ARGAN OIL AND HYDROGLYCERIN EXTRACTS OF BROWN ALGAE, ALARIA ESCULENTA AND MYRIT
FR3026010A1 (en) COMPOSITIONS COMPRISING A COMPOUND OF THE AVERMECTIN FAMILY AND DOXYCYCLINE FOR THE TREATMENT OF ROSACEA
FR3132633A1 (en) Topical composition for its use in the treatment of blepharitis.
EP2821052B1 (en) Combination of miliacin and polar lipids, in particular of sphingolipids and/or phospholipids, for care of the hair and scalp
FR3109301A1 (en) ACTIVE INGREDIENT INCLUDING A SPECIAL EXTRACT OF PUNICA GRANATUM AND USES TO PREVENT AND / OR FIGHT ACNE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PIERRE FABRE DERMO-COSMETIQUE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231201